Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 5101 - 5125 of 10619 in total
Investigational
Sarcosine has been investigated for the treatment of Schizophrenia.
Investigational
Matched Description: … Sarcosine has been investigated for the treatment of Schizophrenia. …
Sisomicin has been used in trials studying the treatment of Pyoderma.
Investigational
Matched Description: … Sisomicin has been used in trials studying the treatment of Pyoderma. …
Sevuparin is under investigation in clinical trial NCT03853421 (Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin).
Investigational
Matched Description: … Subcutaneous Doses of Sevuparin). ... investigation in clinical trial NCT03853421 (Placebo-controlled Study to Determine the Safety and Tolerability of
SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A). SEP-363856 was developed by Sunovion pharmaceuticals....
Investigational
Matched Description: … Additional clinical trials of SEP-363856 are required to confirm the safety and efficacy of this drug ... SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. ... initial clinical study has shown this drug may be effective against both positive and negative symptoms of
Sarconeos is an activator of the MAS receptor.
Investigational
Matched Description: … Sarconeos is an activator of the MAS receptor. …
Investigational
Investigational
SEA-CD70 is an investigational humanized, non-fucosylated monoclonal antibody targeting CD70. SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies).
Investigational
Matched Description: … SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients …
Investigational
SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1) gene.
Investigational
Sutetinib is under investigation in clinical trial NCT05168566 (Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer).
Investigational
Barnidipine is a long-acting novel calcium antagonist that belongs to the dihydropyridine (DHP) group of calcium channel blockers. Used in the treatment of hypertension, barnidipine displays high affinity for the calcium channels of the smooth muscle cells in the vascular wall and selectivity against cardiovascular L-type calcium channels . Barnidipine...
Experimental
Matched Description: … The active component is composed of a single optical isomer (*3'S, 4S* configuration), which is the most ... Used in the treatment of hypertension, barnidipine displays high affinity for the calcium channels of ... potent and longest-acting of the four enantiomers [A31567]. …
Sinefungin is a solid. This compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar. The proteins that adenosyl-ornithine target include RdmB, modification methylase TaqI, rRNA (adenine-N6-)-methyltransferase, and modification methylase RsrI.
Experimental
Experimental
SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).
Investigational
Matched Description: … It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary …
Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.
Investigational
Matched Description: … Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive …
R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated cells. Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex...
Investigational
Matched Description: … Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer ... (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation ... preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of
Investigational
Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
Investigational
Investigational
Sorivudine has been used in trials studying the treatment of Chickenpox and HIV Infections.
Investigational
Matched Description: … Sorivudine has been used in trials studying the treatment of Chickenpox and HIV Infections. …
Sprifermin has been used in trials studying the treatment of Osteoarthritis, Knee and Cartilage Injury of Knee.
Investigational
Matched Description: … of Knee. ... Sprifermin has been used in trials studying the treatment of Osteoarthritis, Knee and Cartilage Injury …
Experimental
Experimental
Displaying drugs 5101 - 5125 of 10619 in total